NRBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NRBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-Revenue measures a company's ability to pay off its debt.
NeuroBo Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.07 Mil. NeuroBo Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.12 Mil. NeuroBo Pharmaceuticals's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.
The historical data trend for NeuroBo Pharmaceuticals's Debt-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroBo Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Revenue | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
NeuroBo Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-Revenue | Get a 7-Day Free Trial | N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, NeuroBo Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NeuroBo Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:
* The bar in red indicates where NeuroBo Pharmaceuticals's Debt-to-Revenue falls into.
Debt-to-Revenue measures a company's ability to pay off its debt.
NeuroBo Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.067 | + | 0.136) | / | N/A | |
= | N/A |
NeuroBo Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.07 | + | 0.117) | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.
Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
James Patrick Tursi | director | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Marshall H Woodworth | officer: Acting Chief Financial Officer | C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
Mark A Glickman | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Joseph Hooker | officer: Interim CEO and President | C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
E&healthcare Investment Fund Ii | 10 percent owner | 16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211 |
E&investment, Inc. | 10 percent owner | 16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000 |
Hyung Heon Kim | director | C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000 |
Andrew I Koven | director | 3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019 |
Na Yeon Kim | director, 10 percent owner | C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115 |
Richard Kang | director | 9451 SUNNYFIELD COURT, POTOMAC MD 20854 |
D Gordon Strickland | director | C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063 |
Ben Gil Price | officer: CEO and President | 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896 |
Akash Bakshi | director, officer: SVP and COO | 602 BAINBRIDGE STREET, FOSTER CITY CA 94404 |
From GuruFocus
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire • 12-01-2023
By PRNewswire PRNewswire • 05-16-2022
By PRNewswire • 01-02-2024
By PRNewswire PRNewswire • 07-15-2022
By PRNewswire • 10-17-2023
By PRNewswire • 08-02-2023
By PRNewswire • 06-27-2023
By PRNewswire • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.